The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase II trial of encorafenib, binimetinib, and cetuximab for early relapsed stage II/III BRAFV600E-mutated colorectal cancer: TRESBIEN trial (OGSG 2101).
 
Toshihiro Kudo
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Merck; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
Shogen Boku
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - Daiichi Sankyo Co. Ltd. (Inst)
 
Atsushi Naito
No Relationships to Disclose
 
Takashi Ohta
No Relationships to Disclose
 
Yusuke Suwa
No Relationships to Disclose
 
Ichiro Takemasa
No Relationships to Disclose
 
Chiaki Inagaki
Honoraria - Astellas Pharma; Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Astellas Pharma
Research Funding - Astellas Pharma; Ono Pharmaceutical
 
Koichi Okuya
No Relationships to Disclose
 
Mitsuyoshi Tei
No Relationships to Disclose
 
Masayoshi Nakanishi
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Astellas Amgen BioPharama; Bristol Myers Squibb Foundation; Lilly; Ono Pharmaceutical
 
Hiroyuki Okuda
No Relationships to Disclose
 
Toshifumi Yamaguchi
Honoraria - MSD Oncology; Ono pharmaceutical., Co LTD
Consulting or Advisory Role - Daiichi Sankyo Company, Limited
 
Shingo Noura
No Relationships to Disclose
 
Yukinori Kurokawa
No Relationships to Disclose
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); SHIONOGI (Inst); Yakult Honsha (Inst)
 
Hironaga Satake
Honoraria - Asahi KASEI; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Guardant Health; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Asahi Kasei (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Yoshinori Kagawa
Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical; Takeda Science Foundation
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical